1. Home
  2. ACAD
  3. ACAD News

Latest ACADIA Pharmaceuticals Inc. (ACAD) News on October 22, 2025

High Growth Tech Stocks in US to Watch for Potential Portfolio Boost
ACAD

Simply Wall St.

16 days ago

High Growth Tech Stocks in US to Watch for Potential Portfolio Boost

Exploring 3 High Growth Tech Stocks in US Market
ACAD

Simply Wall St.

19 days ago

Exploring 3 High Growth Tech Stocks in US Market

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
ACAD

Business Wire

20 days ago

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

Exploring 3 High Growth Tech Stocks in the US Market
ACAD

Simply Wall St.

20 days ago

Exploring 3 High Growth Tech Stocks in the US Market

High Growth Tech Stocks In The US For September 2025
ACAD

Simply Wall St.

22 days ago

High Growth Tech Stocks In The US For September 2025

ACADIA Pharmaceuticals (ACAD) Reports Positive Interim Results From Rett Syndrome Study
ACAD

Simply Wall St.

a month ago

ACADIA Pharmaceuticals (ACAD) Reports Positive Interim Results From Rett Syndrome Study

ACAD

MT Newswires

a month ago

Acadia Pharmaceuticals Reports Gains for Daybue in Rett Syndrome Study

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
ACAD

Business Wire

a month ago

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome
ACAD

Insider Monkey

a month ago

ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome

ACAD

MT Newswires

a month ago

UBS Adjusts Price Target on ACADIA Pharmaceuticals to $39 From $36, Maintains Buy Rating

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

a month ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In US September 2025
ACAD

Simply Wall St.

a month ago

High Growth Tech Stocks To Watch In US September 2025

High Growth Tech Stocks In The US To Watch September 2025
ACAD

Simply Wall St.

2 months ago

High Growth Tech Stocks In The US To Watch September 2025

US High Growth Tech Stocks to Watch
ACAD

Simply Wall St.

2 months ago

US High Growth Tech Stocks to Watch

Exploring US High Growth Tech Stocks with Potential
ACAD

Simply Wall St.

2 months ago

Exploring US High Growth Tech Stocks with Potential

High Growth Tech Stocks To Watch In The US August 2025
ACAD

Simply Wall St.

2 months ago

High Growth Tech Stocks To Watch In The US August 2025

High Growth US Tech Stocks To Watch In August 2025
ACAD

Simply Wall St.

2 months ago

High Growth US Tech Stocks To Watch In August 2025

ACAD

MT Newswires

4 months ago

Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $22 From $19, Maintains Perform Rating

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
ACAD

Business Wire

4 months ago

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

ACAD

Argus Research

4 months ago

ACAD: What does Argus have to say about ACAD?

Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital
ACAD

TipRanks

4 months ago

Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital

ACAD

MT Newswires

4 months ago

RBC Raises Price Target on ACADIA Pharmaceuticals to $38 From $26, Keeps Outperform Rating

Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
ACAD

Insider Monkey

4 months ago

Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent

High Growth Tech Stocks In The US Market June 2025
ACAD

Simply Wall St.

4 months ago

High Growth Tech Stocks In The US Market June 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years
ACAD

Simply Wall St.

4 months ago

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

4 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication
ACAD

Insider Monkey

4 months ago

US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
ACAD

Business Wire

4 months ago

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
ACAD

Business Wire

5 months ago

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
ACAD

Business Wire

5 months ago

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
ACAD

Business Wire

5 months ago

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

ACAD

MT Newswires

5 months ago

Deutsche Bank Upgrades ACADIA Pharmaceuticals to Buy From Hold, Price Target is $20

ACAD

Argus Research

5 months ago

ACAD: Raising target price to $23.00

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

5 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday
ACAD

Insider Monkey

5 months ago

Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday

Biotech Alert: Searches spiking for these stocks today
ACAD

TipRanks

5 months ago

Biotech Alert: Searches spiking for these stocks today

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93
ACAD

Investor's Business Daily

5 months ago

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93

Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer
ACAD

TipRanks

5 months ago

Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer

Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital
ACAD

TipRanks

5 months ago

Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital

ACAD

MT Newswires

5 months ago

Acadia Wins Nuplazid Patent Case in Delaware Court; Shares Surge

ACAD

Argus Research

5 months ago

ACAD: Raising target price to $18.00

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)
ACAD

Zacks

5 months ago

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD

Zacks

5 months ago

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

ACAD

Thomson Reuters StreetEvents

5 months ago

Q1 2025 ACADIA Pharmaceuticals Inc Earnings Call

ACAD

MT Newswires

5 months ago

Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $20 From $22, Maintains Hold Rating

ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
ACAD

GuruFocus.com

5 months ago

ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

ACAD

Associated Press Finance

5 months ago

Acadia: Q1 Earnings Snapshot

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
ACAD

Business Wire

5 months ago

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

ACAD

Argus Research

6 months ago

ACAD: What does Argus have to say about ACAD?

US High Growth Tech Stocks To Watch In Your Portfolio
ACAD

Simply Wall St.

6 months ago

US High Growth Tech Stocks To Watch In Your Portfolio

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
ACAD

Business Wire

6 months ago

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
ACAD

Zacks

6 months ago

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

ACAD

MT Newswires

6 months ago

UBS Adjusts ACADIA Pharmaceuticals Price Target to $22 From $25, Maintains Buy Rating

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
ACAD

Business Wire

6 months ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

ACAD

Argus Research

6 months ago

ACAD: Lowering target price to $15.00

ACAD

MT Newswires

6 months ago

BofA Adjusts Price Target on ACADIA Pharmaceuticals to $18 From $19, Keeps Neutral Rating

ACAD

Argus Research

6 months ago

ACAD: Raising target price to $16.00

Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?
ACAD

Simply Wall St.

6 months ago

Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

6 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACAD

Argus Research

6 months ago

ACAD: Lowering target price to $15.00

ACAD

Argus Research

7 months ago

ACAD: Lowering target price to $17.00

ACAD

Argus Research

7 months ago

ACAD: What does Argus have to say about ACAD?

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts
ACAD

Insider Monkey

7 months ago

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?
ACAD

Insider Monkey

7 months ago

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

7 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
ACAD

Business Wire

7 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
ACAD

Business Wire

8 months ago

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)
ACAD

Zacks

8 months ago

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)

ACAD

Argus Research

8 months ago

ACAD: Lowering target price to $19.00

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)
ACAD

Zacks

8 months ago

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)

ACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
ACAD

Simply Wall St.

8 months ago

ACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
ACAD

Business Wire

8 months ago

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
ACAD

GuruFocus.com

8 months ago

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
ACAD

Simply Wall St.

8 months ago

Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
ACAD

Business Wire

8 months ago

Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ...
ACAD

GuruFocus.com

8 months ago

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ...

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
ACAD

Zacks

8 months ago

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
ACAD

Zacks

8 months ago

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

ACAD

Associated Press Finance

8 months ago

Acadia: Q4 Earnings Snapshot

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
ACAD

Business Wire

8 months ago

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

ACAD

Argus Research

8 months ago

ACAD: Lowering target price to $20.00

ACAD

Argus Research

8 months ago

ACAD: Raising target price to $21.00

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

8 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?
ACAD

Zacks

8 months ago

Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
ACAD

Business Wire

8 months ago

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

ACAD

MT Newswires

8 months ago

Deutsche Bank Initiates Coverage on ACADIA Pharmaceuticals With Hold Rating, $22 Price Target

High Growth Tech Stocks To Watch In February 2025
ACAD

Simply Wall St.

9 months ago

High Growth Tech Stocks To Watch In February 2025

ACAD

Argus Research

9 months ago

ACAD: Raising target price to $20.00

ACAD

Argus Research

9 months ago

ACAD: What does Argus have to say about ACAD?

ACAD

Argus Research

9 months ago

ACAD: Raising target price to $19.00

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD

Business Wire

9 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACAD

Argus Research

9 months ago

ACAD: What does Argus have to say about ACAD?

Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025
ACAD

GuruFocus.com

9 months ago

Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025

ACAD

MT Newswires

9 months ago

Acadia Pharmaceuticals Seeks EU Marketing Approval for Rett Syndrome Treatment

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
ACAD

Business Wire

9 months ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
ACAD

Business Wire

9 months ago

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20?
ACAD

Insider Monkey

9 months ago

Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20?

Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61%
ACAD

Simply Wall St.

9 months ago

Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61%

ACAD

MT Newswires

10 months ago

Guggenheim Downgrades ACADIA Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $20 From $23

Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing
ACAD

Insider Monkey

10 months ago

Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing

Share on Social Networks: